Fierce Biotech May 7, 2024
Lykos Therapeutics’ MDMA-assisted therapy is charting yet another first in the psychedelic field: an FDA advisory meeting.
The biotech will meet with the Psychopharmacologic Drugs Advisory Committee on June 4, according to a late Monday release. This will be the first time that FDA experts will formally debate a psychedelic treatment. Lykos (formerly known as MAPS PBC) is seeking FDA approval to use MDMA to treat patients with post-traumatic stress disorder. The drug is commonly referred to as ecstasy.
this will also be the first time in 25 years that the FDA will review a new treatment for PTSD, according to Lykos’ announcement.
Lykos has been the leading company in the psychedelic space, a field that has seen...
Today's Sponsors
Today's Sponsor